Infanrixtetra

Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin, the active ingredient in Infanrixtetra, is a vaccine presented as an injectable formulation for intramuscular use. It induces immunity against poliovirus type 3 and pertussis, protecting children and adults from paralytic polio and whooping cough. GNH USA supplies Infanrixtetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrixtetra is a combined inactivated poliovirus type 3 and pertussis filamentous haemagglutinin vaccine used to prevent viral and bacterial respiratory infections. - Poliomyelitis (type 3): provides active immunity that reduces the risk of paralytic disease caused by poliovirus type 3. - Pertussis (whooping cough): induces antibodies against pertussis filamentous haemagglutinin, helping prevent whooping cough. - Community protection: contributes to herd immunity against both poliomyelitis and pertussis, supporting public‑health immunisation programmes.

Vaccination may be accompanied by mild, transient reactions.

Common Side Effects: - Injection site pain, redness or swelling. - Low‑grade fever. - Headache or mild fatigue. - Transient muscle aches.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Seizures (rare). - Guillain‑Barré syndrome. - High fever persisting >48 hours. - Neurologic complications such as encephalitis.

Infanrixtetra should be administered with attention to specific safety considerations. - Allergy to vaccine components: avoid if severe hypersensitivity is known. - Immunocompromised individuals: assess risk‑benefit before use. - Acute febrile illness: defer vaccination until recovery. - Pregnancy: use only if potential benefits outweigh uncertain risks. - Breastfeeding: no specific contraindication, but monitor infant for reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that modify immune response.

Major Interactions (Avoid): - Concurrent administration of blood products containing immunoglobulins: may diminish vaccine‑induced immunity. - Live viral vaccines given within 4 weeks: increased risk of interference with immune response.

Moderate Interactions (Monitor Closely): - Simultaneous receipt of other inactivated vaccines: generally safe but monitor for additive reactogenicity. - Immunosuppressive therapy (e.g., high‑dose steroids): may reduce antibody production. - Antipyretics taken prophylactically: may blunt expected mild fever response.